Chemotherapy response assessment in stage IV melanoma patients - Comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 10, 2008, Pages 1786-1795

  Strobel, Klaus ^a   Dummer, Reinhard ^b   Steinert, Hans C ^a   Conzett, Katrin Baumann ^b   Schad, Karin ^b   Lago, Marisol Pérez ^a   Soyka, Jan D ^a   Veit Haibach, P ^a   Seifert, Burkhardt ^c   Kalff, V ^a,d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d ALFRED HOSPITAL   (Australia)

Author keywords

18F FDG PET; Metastasis; Oncology PET CT PET; Therapy

Indexed keywords

CISPLATIN; DACARBAZINE; FLUORODEOXYGLUCOSE F 18; PROTEIN S100B; TEMOZOLOMIDE; THALIDOMIDE; VINDESINE;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BRAIN SCINTIANGIOGRAPHY; CANCER LOCALIZATION; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; MELANOMA; NEURORADIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRAIN; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MELANOMA; MIDDLE AGED; NERVE GROWTH FACTORS; OUTCOME ASSESSMENT (HEALTH CARE); POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; S100 PROTEINS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; SURVIVAL ANALYSIS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 52449109702     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-008-0806-1     Document Type: Article

References (37)

1. TK Eigentler UM Caroli P Radny C Garbe 2003 Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials Lancet Oncol. 4 748 759
2. A Barth LA Wanek DL Morton 1995 Prognostic factors in 1,521 melanoma patients with distant metastases J Am Coll Surg. 181 193 201
3. D Schadendorf 2002 Is there a standard for the palliative treatment of melanoma Onkologie 25 74 76
4. L Serrone P Hersey 1999 The chemoresistance of human malignant melanoma: an update Melanoma Res. 9 51 58
5. MJ Reinhardt AY Joe U Jaeger 2006 Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients J Clin Oncol. 24 1178 1187
6. K Strobel R Dummer DB Husarik M Perez Lago TF Hany HC Steinert 2007 High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases Radiology 244 566 574
7. K Strobel J Skalsky V Kalff 2007 Tumour assessment in advanced melanoma: value of FDG-PET/CT in patients with elevated serum S-100B Eur J Nucl Med Mol Imaging. 34 1366 1375
8. MJ Dalrymple-Hay PD Rome C Kennedy M Fulham BC McCaughan 2002 Pulmonary metastatic melanoma-the survival benefit associated with positron emission tomography scanning Eur J Cardiothorac Surg. 21 611 614
9. ME Juweid BD Cheson 2005 Role of positron emission tomography in lymphoma J Clin Oncol. 23 4577 4580
10. ME Juweid BD Cheson 2006 Positron-emission tomography and assessment of cancer therapy N Engl J Med. 354 496 507
11. G Jerusalem R Hustinx Y Beguin G Fillet 2005 Evaluation of therapy for lymphoma Semin Nucl Med. 35 186 196
12. K Ott WA Weber F Lordick 2006 Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction J Clin Oncol. 24 4692 4698
13. F Lordick K Ott BJ Krause 2007 PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial Lancet Oncol. 8 797 805
14. CJ Hoekstra SG Stroobants EF Smit 2005 Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-d-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer J Clin Oncol. 23 8362 8370
15. J Dose Schwarz M Bader L Jenicke G Hemminger F Janicke N Avril 2005 Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET J Nucl Med. 46 1144 1150
16. K Strobel J Skalsky HC Steinert 2007 S-100B and FDG-PET/CT in therapy response assessment of melanoma patients Dermatology 215 192 201
17. ER Ryan AD Hill SJ Skehan 2006 FDG PET/CT demonstrates the effectiveness of isolated limb infusion for malignant melanoma Clin Nucl Med. 31 707 708
18. HD Abraha LC Fuller AW Du Vivier EM Higgins RA Sherwood 1997 Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma Br J Dermatol. 137 381 385
19. R Andres JI Mayordomo P Zaballos 2004 Prognostic value of serum S-100B in malignant melanoma Tumori 90 607 610
20. T Banfalvi K Gilde M Boldizsar T Kremmer S Otto 1999 Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression Pathol Oncol Res. 5 218 222
21. J Domingo-Domenech R Molina T Castel 2005 Serum protein s-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon-comparison with tyrosinase rt-PCR Oncology 68 341 349
22. HB Guo B Stoffel-Wagner T Bierwirth J Mezger D Klingmuller 1995 Clinical significance of serum S100 in metastatic malignant melanoma Eur J Cancer. 31A 1898 1902
23. AP Hamberg CM Korse JM Bonfrer GC de Gast 2003 Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma Melanoma Res. 13 45 49
24. D Delbeke RE Coleman MJ Guiberteau 2006 Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0 J Nucl Med. 47 885 895
25. P Therasse SG Arbuck EA Eisenhauer 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst. 92 205 216
26. EM Rohren JM Provenzale DP Barboriak RE Coleman 2003 Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy Radiology 226 181 187
27. S Holtas S Cronqvist 1981 Cranial computed tomography of patients with malignant melanoma Neuroradiology 22 123 127
28. G Henze R Dummer HI Joller-Jemelka R Boni G Burg 1997 Serum S100-a marker for disease monitoring in metastatic melanoma Dermatology 194 208 212
29. A Hauschild G Engel W Brenner 1999 Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy Br J Dermatol. 140 1065 1071
30. WA Weber R Figlin 2007 Monitoring cancer treatment with PET/CT: does it make a difference J Nucl Med. 48 Suppl 1 36S 44S
31. M Hutchings A Loft M Hansen 2006 FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma Blood 107 52 59
32. LF de Geus-Oei HF van der Heijden EP Visser 2007 Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer J Nucl Med. 48 1592 1598
33. C Lin E Itti C Haioun 2007 Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis J Nucl Med. 48 1626 1632
34. ME Juweid S Stroobants OS Hoekstra 2007 Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma J Clin Oncol. 25 571 578
35. M Majer RL Jensen DC Shrieve 2007 Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases Cancer 110 1329 1337
36. KM Fife MH Colman GN Stevens 2004 Determinants of outcome in melanoma patients with cerebral metastases J Clin Oncol. 22 1293 1300
37. DR Budman E Camacho RE Wittes 1978 The current causes of death in patients with malignant melanoma Eur J Cancer. 14 327 330